Feb 14, 2024 / 08:30AM GMT
Operator
Welcome to BioArctic Q4 report 2023 for the first part of the conference call. (Operator Instructions) Now I will hand the conference over to CEO, Gunilla Osswald; and CFO, Anders Martin-Löf, please go ahead.
Gunilla Osswald - BioArctic AB(publ)-CEO
Good morning, and welcome to buy BioArctic presentation for the fourth quarter and for the full year of 2023 I'm Gunilla Osswald and I'm CEO of BioArctic, and I will share today's presentation with our CFO, Anders Martin-Löf.
It's very exciting times to BioArctic with lecanemab being the first and only disease-modifying treatment with a full approval in the US and Japan and now also in China, it's the beginning of a new era and BioArctic is behind this true breakthrough in the treatment of Alzheimer's disease. I find it extremely gratifying that we now can help a large number of patients and their families, and I'll talk more about that here today.
Next slide, please. BioArctic is listed at Nasdaq, Stockholm, Large-Cap, and this is our disclaimer.
Next
Q4 2023 BioArctic AB Earnings Call Transcript
Feb 14, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers